Literature DB >> 2822649

The effect of cultural conditions on the activity of LY146032 against staphylococci and streptococci.

J H Andrew1, M C Wale, L J Wale, D Greenwood.   

Abstract

The antibacterial activity of LY146032 was greatly potentiated in the presence of calcium ions. In the presence of a physiological concentration of calcium (ca 100 mg/l: 2.5 mM) the new compound was more active than vancomycin or teicoplanin against a selection of clinical isolates of staphylococci and streptococci. The requirement for calcium could not be satisfied by magnesium. The activity of LY146032 varied when tested in different culture media, including batches of Mueller-Hinton agar from different manufacturers. The highest minimum inhibitory concentrations of LY146032 were observed in tests on Iso-Sensitest agar, which contains little calcium. Supplementation of Iso-Sensitest agar with increasing concentrations of calcium caused a proportionate fall in the MIC of LY146032. Saponin-lysed horse blood; incubation in a CO2-rich atmosphere; and an increase in the bacterial inoculum from 10(3) to 10(6) cfu/spot had little effect on the activity of LY146032 in the presence or absence of calcium.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822649     DOI: 10.1093/jac/20.2.213

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  20 in total

1.  The relative contributions of physical structure and cell density to the antibiotic susceptibility of bacteria in biofilms.

Authors:  Amy E Kirby; Kimberly Garner; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

2.  Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.

Authors:  Bruce R Levin; Klas I Udekwu
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

3.  Effects of reduced cation supplement recommendations (National Committee for Clinical Laboratory Standards) on daptomycin antistaphylococcal activity.

Authors:  R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Authors:  W E Alborn; N E Allen; D A Preston
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

5.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model.

Authors:  J I Blenkharn; J H Darrell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs.

Authors:  H Hanberger; L E Nilsson; R Maller; B Isaksson
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.

Authors:  Jared A Silverman; Nancy G Perlmutter; Howard M Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Turbidimetric response of Staphylococcus aureus and Enterococcus faecalis to daptomycin.

Authors:  M C Wale; L J Wale; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

10.  Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin.

Authors:  Anne-Kathrin John; Daniela Baldoni; Manuel Haschke; Katharina Rentsch; Patrick Schaerli; Werner Zimmerli; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.